HK1086270A1 - Benzothiazole derivative compounds, compositions and uses - Google Patents

Benzothiazole derivative compounds, compositions and uses

Info

Publication number
HK1086270A1
HK1086270A1 HK06107502.0A HK06107502A HK1086270A1 HK 1086270 A1 HK1086270 A1 HK 1086270A1 HK 06107502 A HK06107502 A HK 06107502A HK 1086270 A1 HK1086270 A1 HK 1086270A1
Authority
HK
Hong Kong
Prior art keywords
compositions
derivative compounds
benzothiazole derivative
benzothiazole
compounds
Prior art date
Application number
HK06107502.0A
Other languages
English (en)
Inventor
William E Klunk
Jr Chester A Mathis
Yanming Wang
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/388,173 external-priority patent/US7270800B2/en
Priority claimed from US10/645,847 external-priority patent/US20050043523A1/en
Priority claimed from PCT/US2004/007797 external-priority patent/WO2004083195A1/en
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of HK1086270A1 publication Critical patent/HK1086270A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HK06107502.0A 2003-03-14 2006-07-04 Benzothiazole derivative compounds, compositions and uses HK1086270A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/388,173 US7270800B2 (en) 2000-08-24 2003-03-14 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses
PCT/US2004/007797 WO2004083195A1 (en) 2003-03-14 2004-03-15 Benzothiazole derivative compounds, compositions and uses

Publications (1)

Publication Number Publication Date
HK1086270A1 true HK1086270A1 (en) 2006-09-15

Family

ID=35057877

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107502.0A HK1086270A1 (en) 2003-03-14 2006-07-04 Benzothiazole derivative compounds, compositions and uses

Country Status (16)

Country Link
EP (1) EP1611115B1 (xx)
JP (1) JP4875487B2 (xx)
CN (2) CN102532055B (xx)
AU (2) AU2004221897B2 (xx)
BE (1) BE2015C005I2 (xx)
BR (1) BRPI0408274B8 (xx)
CY (2) CY1113334T1 (xx)
DK (1) DK1611115T3 (xx)
ES (1) ES2393921T3 (xx)
HK (1) HK1086270A1 (xx)
HU (1) HUS1500006I1 (xx)
NO (3) NO330861B1 (xx)
PL (1) PL1611115T3 (xx)
PT (1) PT1611115E (xx)
RU (1) RU2440995C2 (xx)
SI (1) SI1611115T1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
ES2536449T3 (es) 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Derivados de tioflavina para uso en diagnosis de la enfermedad de Alzheimer
US7868033B2 (en) * 2004-05-20 2011-01-11 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
WO2008093057A1 (en) * 2007-01-30 2008-08-07 Ge Healthcare Limited Tools for aiding in the diagnosis of neurodegenerative diseases
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
JP2011529086A (ja) * 2008-07-24 2011-12-01 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド Ａｄ病変を同定するために有用な造影剤
CA2737028C (en) * 2008-09-23 2017-06-27 Wista Laboratories Ltd. Ligands for aggregated tau molecules
RU2671506C2 (ru) * 2013-09-26 2018-11-01 Ф. Хоффманн-Ля Рош Аг Имидазо[1,2-а]пиридин-7-амины в качестве средств визуализации
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
CN103613589B (zh) * 2013-11-29 2016-03-30 江苏华益科技有限公司 一种用于神经退行性疾病领域的新型pet显像剂前体及标准品的合成方法
EP3190888B1 (en) * 2014-08-29 2020-06-10 CHDI Foundation, Inc. Probes for imaging huntingtin protein
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
GR1009516B (el) * 2018-03-22 2019-05-02 Εκεφε Δημοκριτος Τρικαρβονυλο-συμπλοκα μεταλλων μεταπτωσεως με βενζο-ετεροκυκλικο παραγωγο του κυκλοπενταδιενυλικου ανιοντος με υψηλη διαπερατοτητα του αιματοεγκεφαλικου φραγμου για εφαρμογες στη διαγνωση και θεραπεια νοσων του κνς

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001383A3 (en) * 1996-11-22 2001-11-28 Lilly Co Eli N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same and their use
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
ES2536449T3 (es) * 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Derivados de tioflavina para uso en diagnosis de la enfermedad de Alzheimer
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
US6696039B2 (en) * 2001-04-23 2004-02-24 Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
GB0229686D0 (en) * 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles

Also Published As

Publication number Publication date
AU2004221897A9 (en) 2009-08-20
AU2004221897A2 (en) 2004-09-30
CN102532055A (zh) 2012-07-04
NO20054674L (no) 2005-12-13
BRPI0408274B8 (pt) 2021-05-25
CN102532055B (zh) 2016-05-11
AU2004221897B2 (en) 2010-11-18
PT1611115E (pt) 2012-12-07
RU2005131872A (ru) 2006-02-27
RU2440995C2 (ru) 2012-01-27
DK1611115T3 (da) 2012-11-26
AU2004221897A1 (en) 2004-09-30
AU2011200667B2 (en) 2011-12-22
BE2015C005I2 (xx) 2023-03-07
HUS1500006I1 (hu) 2015-02-18
JP4875487B2 (ja) 2012-02-15
BRPI0408274A (pt) 2006-03-21
NO2015005I1 (no) 2015-03-02
NO2015005I2 (no) 2015-02-18
SI1611115T1 (sl) 2012-12-31
CN1784392A (zh) 2006-06-07
NO20054674D0 (no) 2005-10-11
EP1611115A1 (en) 2006-01-04
CY1113334T1 (el) 2015-12-09
NO20110980L (no) 2005-12-13
BRPI0408274B1 (pt) 2019-02-26
PL1611115T3 (pl) 2013-01-31
CY2015007I1 (el) 2015-12-09
JP2006522104A (ja) 2006-09-28
EP1611115B1 (en) 2012-08-22
NO330861B1 (no) 2011-08-01
ES2393921T3 (es) 2013-01-02
AU2011200667A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
HUS1500006I1 (hu) Benzotiazol-származék vegyületek, kompozíciók és alkalmazások
EP1646382A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1692112A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
ZA200606027B (en) Thiazole derivative
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (en) COMPOUNDS, METHODS AND COMPOSITIONS
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
IL175300A0 (en) Indirubin-type compounds, compositions, and methods for their use
HK1070656A1 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
AU2003299612A8 (en) Compounds, compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
PL374833A1 (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor
AU2003290507A8 (en) Compounds, compositions and methods
EP1675834A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
AU2003277079A8 (en) Compounds, compositions, and methods
EP1680420A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1594849A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
GB0307695D0 (en) Compounds,compositions and processes
EP1620092A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
AU2003267169A8 (en) Compounds, compositions and methods
AU2003300031A8 (en) Compounds, compositions, and methods
EP1706111A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1593684A4 (en) NEW COMPOUND CALL CAPRAZENE AND DERIVATIVES THEREOF AND NOVEL COMPOUND CALL CAPRAZOL AND DERIVATIVES THEREOF

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240314